Clinical Trial Update: Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating atorvastatin for reducing 28-day mortality in COVID-19; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Pneumonia

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: Mansoura University | Conditions: Covid19, SARS-CoV2 Infection | Phase 3 | Status: UNKNOWN